glp 1 contraindications pancreatitis agonist side effects Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Consensus Recommendations on GLP-1 RA

doi: 10.1371/journal.pone.0208225

The EMA stated that NAION may affect up to 1 in 10,000 people taking semaglutide and recommended that semaglutide treatment be stopped if NAION is confirmed

In June 2025, the TGA issued a medicines safety update requiring consideration be given to the risk of delayed gastric emptying and aspiration when providing anaesthesia or deep sedation for patients using these drugs

Bodyweight exercises, resistance bands, or dumbbells at home provide sufficient stimulus

This document outlines the implications of losing or dropping FEHB coverage and not having prescription drug coverage for 63 days or longer

[32], involving 99 HS patients, identified several significant factors contributing to the development of diabetes in this population